Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1.
Marcela Cataldi, Nirav R Shah, Sébastien A Felt, Valery Z Grdzelishvili
文献索引:Virology 485 , 340-54, (2015)
全文:HTML全文
摘要
Vesicular stomatitis virus (VSV) is an effective oncolytic virus against most human pancreatic ductal adenocarcinoma (PDAC) cell lines. However, some PDAC cell lines are highly resistant to oncolytic VSV-ΔM51 infection. To better understand the mechanism of resistance, we tested a panel of 16 small molecule inhibitors of different cellular signaling pathways, and identified TPCA-1 (IKK-β inhibitor) and ruxolitinib (JAK1/2 inhibitor), as strong enhancers of VSV-ΔM51 replication and virus-mediated oncolysis in all VSV-resistant PDAC cell lines. Both TPCA-1 and ruxolitinib similarly inhibited STAT1 and STAT2 phosphorylation and decreased expression of antiviral genes MxA and OAS. Moreover, an in situ kinase assay provided biochemical evidence that TPCA-1 directly inhibits JAK1 kinase activity. Together, our data demonstrate that TPCA-1 is a unique dual inhibitor of IKK-β and JAK1 kinase, and provide a new evidence that upregulated type I interferon signaling plays a major role in resistance of pancreatic cancer cells to oncolytic viruses. Copyright © 2015 Elsevier Inc. All rights reserved.
相关化合物
相关文献:
2014-12-16
[Nucleic Acids Res. 42(22) , 14022-30, (2014)]
2014-10-01
[Biochim. Biophys. Acta 1838(10) , 2615-24, (2014)]
2015-01-01
[Drug Dev. Ind. Pharm. 41(1) , 156-62, (2014)]
2014-01-01
[PLoS ONE 9(11) , e112818, (2014)]
2015-03-01
[Tissue Eng. Part A 21(5-6) , 948-59, (2015)]